Bio-Techne Corporation (TECH) financial statements: income statement, balance sheet and cash flow

Bio-Techne Corporation's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Jun 30, 2026 · FY), Bio-Techne Corporation reported revenue of $1.2B (-0.4% year on year) and net income of $181.9M (+147.8% year on year).

Income statement

Bio-Techne Corporation income statement, fiscal years

Line item	Jun 30, 2026 · FY	Jun 30, 2025 · FY	Jun 30, 2024 · FY	Jun 30, 2023 · FY
Net sales	$1.2B	$1.2B	$1.2B	$1.1B
Cost of sales	$416.0M	$429.4M	$389.3M	$366.9M
Gross margin	$799.1M	$790.3M	$769.7M	$769.8M
Selling, general and administrative	$452.4M	$588.5M	$466.4M	$378.4M
Research and development	$94.8M	$99.5M	$96.7M	$92.5M
Total operating expenses	$547.2M	$688.0M	$563.0M	$470.9M
Operating income	$251.9M	$102.3M	$206.7M	$298.9M
Interest expense	($9.6M)	($8.5M)	($15.7M)	($11.2M)
Interest income	$4.2M	$3.9M	$3.3M	$3.4M
Other non-operating income (expense), net	($5.8M)	$831.0K	($8.6M)	$47.5M
Total other income (expense), net	($11.2M)	($3.8M)	($21.0M)	$39.7M
Earnings before income taxes	$240.7M	$98.5M	$185.7M	$338.7M
Income taxes	$58.8M	$25.1M	$17.6M	$53.2M
Net earnings	$181.9M	$73.4M	$168.1M	$285.4M
Foreign currency translation income (loss)	($8.2M)	$24.0M	($7.5M)	$4.2M
Unrealized losses on derivative instruments	($2.5M)	($5.6M)	($4.8M)	$4.8M
Other comprehensive income (loss)	($10.7M)	$18.4M	($12.3M)	$9.1M
Comprehensive income	$171.2M	$91.8M	$155.9M	$294.4M
Basic (in dollars per share)	$1.17	$0.47	$1.07	$1.81
Diluted (in dollars per share)	$1.16	$0.46	$1.05	$1.76
Basic (in shares)	156.0M	157.5M	157.7M	157.2M
Diluted (in shares)	157.0M	159.7M	160.8M	161.9M

Bio-Techne Corporation income statement, quarters

Line item	Mar 31, 2026 · Q3	Dec 31, 2025 · Q2	Sep 30, 2025 · Q1	Mar 31, 2025 · Q3
Net sales	$311.4M	$295.9M	$286.6M	$316.2M
Cost of sales	$103.1M	$104.6M	$98.4M	$101.6M
Gross margin	$208.3M	$191.3M	$188.1M	$214.6M
Selling, general and administrative	$109.3M	$113.7M	$116.2M	$151.3M
Research and development	$23.5M	$23.1M	$24.2M	$24.6M
Total operating expenses	$132.8M	$136.8M	$140.5M	$175.8M
Operating income	$75.5M	$54.5M	$47.7M	$38.7M
Other income (expense)	($4.3M)	($3.7M)	$333.0K	($434.0K)
Earnings before income taxes	$71.2M	$50.8M	$48.0M	$38.3M
Income taxes	$20.2M	$12.8M	$9.8M	$15.7M
Net earnings	$51.0M	$38.0M	$38.2M	$22.6M
Foreign currency translation income (loss)	($4.4M)	$2.8M	($2.9M)	$5.3M
Unrealized gains (losses) on derivative instruments	($160.0K)	($711.0K)	($1.7M)	($1.7M)
Other comprehensive income (loss)	($4.5M)	$2.1M	($4.5M)	$3.6M
Comprehensive income	$46.5M	$40.1M	$33.7M	$26.2M
Basic (in dollars per share)	$0.33	$0.24	$0.25	$0.14
Diluted (in dollars per share)	$0.32	$0.24	$0.24	$0.14
Basic (in shares)	156.3M	155.8M	155.5M	157.4M
Diluted (in shares)	157.4M	157.0M	156.4M	158.9M

Balance sheet

Bio-Techne Corporation balance sheet, fiscal years

Line item	Jun 30, 2026 · FY	Jun 30, 2025 · FY	Jun 30, 2024 · FY	Jun 30, 2023 · FY
Cash and cash equivalents	$264.7M	$162.2M	$151.8M	$180.6M
Accounts receivable, less allowances of $4,644 and $4,215, respectively	$216.6M	$206.9M	$241.4M	$218.5M
Inventories	$195.7M	$189.4M	$179.7M	$171.6M
Other current assets	$67.4M	$37.5M	$33.7M	$27.1M
Total current assets	$744.4M	$608.3M	$617.4M	$621.5M
Property and equipment, net	$231.8M	$245.7M	$251.2M	$226.2M
Right-of-use assets	$67.3M	$73.4M	$91.3M	$98.3M
Goodwill	$975.4M	$980.9M	$972.7M	$872.7M
Intangible assets, net	$303.5M	$365.6M	$507.1M	$534.6M
Other assets	$264.3M	$273.6M	$264.3M	$285.3M
Total assets	$2.6B	$2.6B	$2.7B	$2.6B
Trade accounts payable	$26.7M	$25.3M	$38.0M	$25.7M
Salaries, wages and related accruals	$57.9M	$65.8M	$49.8M	$36.7M
Accrued expenses	$20.5M	$25.7M	$24.9M	$14.9M
Contract liabilities	$36.1M	$32.6M	$27.9M	$23.1M
Income taxes payable	$3.6M	$10.8M	$3.7M	$12.0M
Operating lease liabilities - current	$14.9M	$14.1M	$12.9M	$11.2M
Other current liabilities	$4.0M	$1.6M	$2.2M	$1.4M
Total current liabilities	$163.7M	$175.8M	$159.4M	$128.5M
Deferred income taxes	$19.3M	$6.2M	$55.9M	$89.0M
Long-term debt obligations	$200.0M	$346.0M	$319.0M	$350.0M
Operating lease liabilities	$74.2M	$84.0M	$87.6M	$93.8M
Other long-term liabilities	$21.3M	$27.1M	$13.2M	$10.9M
Undesignated capital stock, par value $.01 per share; authorized 5,000,000 shares; none issued or outstanding	$0.00	$0.00	$0.00	$0.00
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 156,095,113 and 154,972,196 respectively	$1561000.00	$1550000.00	$1582000.00	$1576000.00
Additional paid-in capital	$1.0B	$911.1M	$820.3M	$721.5M
Retained earnings	$1.1B	$1.1B	$1.3B	$1.3B
Accumulated other comprehensive loss	($70.6M)	($59.9M)	($78.3M)	($66.1M)
Total shareholders' equity	$2.1B	—	$2.1B	$2.0B
Total liabilities and shareholders' equity	$2.6B	$2.6B	$2.7B	$2.6B

Bio-Techne Corporation balance sheet, quarters

Line item	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025
Cash and cash equivalents	$209.8M	$172.9M	$145.0M	$140.7M
Accounts receivable, less allowances of $4,415 and $4,215, respectively	$214.6M	$184.6M	$183.9M	$237.1M
Inventories	$201.2M	$205.4M	$203.2M	$191.1M
Other current assets	$62.5M	$74.5M	$77.5M	$53.6M
Total current assets	$688.0M	$637.4M	$609.5M	$627.2M
Property and equipment, net	$233.0M	$234.4M	$240.3M	$252.0M
Right-of-use assets	$68.3M	$68.2M	$70.7M	$83.7M
Goodwill	$977.8M	$980.6M	$978.9M	$968.6M
Intangible assets, net	$319.1M	$335.0M	$350.1M	$443.7M
Other assets	$264.4M	$267.1M	$276.6M	$269.0M
Total assets	$2.6B	$2.5B	$2.5B	$2.6B
Trade accounts payable	$23.5M	$26.3M	$30.2M	$31.6M
Salaries, wages and related accruals	$54.4M	$45.0M	$43.6M	$61.9M
Accrued expenses	$17.7M	$20.3M	$19.2M	$23.9M
Contract liabilities	$38.4M	$31.0M	$30.4M	$32.3M
Income taxes payable	$3.0M	$2.5M	$2.8M	$3.6M
Operating lease liabilities - current	$14.2M	$13.7M	$13.8M	$14.0M
Other current liabilities	$2.1M	$1.6M	$4.5M	$1.8M
Total current liabilities	$153.3M	$140.4M	$144.5M	$169.2M
Deferred income taxes	$14.2M	$11.0M	$11.3M	$31.9M
Long-term debt obligations	$200.0M	$260.0M	$300.0M	$330.0M
Operating lease liabilities	$76.1M	$77.2M	$80.7M	$79.5M
Other long-term liabilities	$21.7M	$23.1M	$23.8M	$15.7M
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0	0	0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 156,516,091 and 154,972,196 respectively	$1565000.00	$1559000.00	$1557000.00	$1568000.00
Additional paid-in capital	$1.0B	$965.0M	$946.1M	$902.1M
Retained earnings	$1.1B	$1.1B	$1.1B	$1.2B
Accumulated other comprehensive loss	($66.9M)	($62.3M)	($64.4M)	($82.1M)
Total shareholders' equity	$2.1B	$2.0B	$2.0B	$2.0B
Total liabilities and shareholders' equity	$2.6B	$2.5B	$2.5B	$2.6B

Cash flow statement

Bio-Techne Corporation cash flow statement, fiscal years

Line item	Jun 30, 2026 · FY	Jun 30, 2025 · FY	Jun 30, 2024 · FY	Jun 30, 2023 · FY
Net earnings	$181.9M	$73.4M	$168.1M	$285.4M
Depreciation and amortization	$97.4M	$109.9M	$111.7M	$107.2M
Deferred income taxes	$13.2M	($51.1M)	($39.4M)	($29.6M)
Stock-based compensation expense	$41.4M	$40.8M	$38.0M	$39.2M
(Gain) Loss on equity method investment	($887.0K)	($938.0K)	—	$1.1M
Loss on investments	$5.9M	—	—	—
Asset impairment restructuring	$3.9M	$21.3M	$2.6M	—
Leases, net	($3.0M)	$685.0K	$1.7M	$2.1M
(Recovery) Impairment of assets held-for-sale	($6.8M)	—	—	—
Other operating activity	$477.0K	$675.0K	$584.0K	$455.0K
Trade accounts and other receivables, net	($10.8M)	$34.1M	($20.5M)	($20.9M)
Inventories	($8.2M)	($18.1M)	($14.2M)	($30.2M)
Prepaid expenses	$5.3M	($14.4M)	($3.1M)	($4.6M)
Trade accounts payable, accrued expenses, contract liabilities, and other	$3.2M	($14.0M)	$25.8M	($7.9M)
Salaries, wages and related accruals	($7.7M)	$15.4M	$12.6M	($24.6M)
Income taxes payable	($23.1M)	$8.5M	($10.6M)	($2.5M)
Net cash provided by operating activities	$292.1M	$287.6M	$299.0M	$254.4M
Additions to property and equipment	($28.9M)	($31.0M)	($62.9M)	($38.2M)
Distributions from Wilson Wolf	$6.0M	—	—	—
Proceeds from sale of assets held-for-sale	$4.6M	$2.4M	—	—
Net cash used in investing activities	($18.2M)	($35.2M)	($203.0M)	($265.6M)
Cash dividends	($49.9M)	($50.4M)	($50.4M)	($50.3M)
Proceeds from stock option exercises	$80.6M	$51.7M	$60.9M	$29.8M
Repurchases of common stock	($41.7M)	($275.7M)	($80.0M)	($19.6M)
Repayments of long-term debt	($146.0M)	($77.0M)	($256.0M)	($525.7M)
Taxes paid on RSUs and net share settlements	($12.1M)	($6.5M)	($21.9M)	($28.9M)
Net cash used in financing activities	($169.1M)	($253.9M)	($122.4M)	$22.6M
Effect of exchange rate changes on cash and cash equivalents	($2.2M)	$11.9M	($2.3M)	($3.4M)
Net change in cash and cash equivalents	$102.5M	$10.4M	($28.8M)	$8.0M
Cash and cash equivalents at beginning of period	$162.2M	$151.8M	$180.6M	$172.6M
Cash and cash equivalents at end of period	$264.7M	$162.2M	$151.8M	$180.6M

Bio-Techne Corporation cash flow statement, quarters

Line item	Mar 31, 2026 · YTD	Dec 31, 2025 · YTD	Sep 30, 2025 · Q1	Mar 31, 2025 · YTD
Net earnings	$127.2M	$76.2M	$38.2M	$91.1M
Depreciation and amortization	$73.2M	$49.0M	$24.3M	$82.8M
Deferred income taxes	$8.0M	$5.2M	$5.3M	($18.8M)
Stock-based compensation expense	$36.1M	$25.6M	$11.7M	$36.3M
(Gain) Loss on equity method investment	$335.0K	($404.0K)	($294.0K)	$169.0K
(Gain) Loss on investments	$2.3M	($37.0K)	($2.1M)	—
Asset impairment restructuring	$3.3M	$3.3M	—	$10.0M
Leases, net	($2.6M)	($1.8M)	($912.0K)	$502.0K
Recovery of assets held-for-sale	($6.8M)	($6.8M)	($6.8M)	—
Other operating activity	$621.0K	$663.0K	$1.0M	$527.0K
Trade accounts and other receivables, net	($7.9M)	$23.3M	$22.4M	$5.3M
Inventories	($12.5M)	($15.9M)	($14.0M)	($11.5M)
Prepaid expenses	$2.5M	$3.3M	$380.0K	($7.2M)
Trade accounts payable, accrued expenses, contract liabilities, and other	($3.0M)	($8.1M)	($2.1M)	($639.0K)
Salaries, wages and related accruals	($11.2M)	($20.7M)	($22.1M)	$12.0M
Income taxes payable	($13.0M)	($22.8M)	($27.4M)	($7.9M)
Net cash provided by (used in) operating activities	$196.7M	$110.0M	$27.6M	$189.4M
Additions to property and equipment	($20.4M)	($11.3M)	($5.4M)	($26.1M)
Distributions from Wilson Wolf	$4.6M	$1.4M	$1.4M	$2.7M
Proceeds from sale of assets held-for-sale	$4.6M	$4.6M	$4.6M	$1.8M
Net cash provided by (used in) investing activities	($11.1M)	($5.3M)	$605.0K	($35.6M)
Cash dividends	($37.4M)	($24.9M)	($12.4M)	($38.0M)
Proceeds from stock option exercises	$58.2M	$28.2M	$23.5M	$45.5M
Repurchases of common stock	($24.0K)	($24.0K)	($24.0K)	($175.7M)
Borrowings under line-of-credit agreement	$0	—	—	$38.0M
Repayments of long-term debt	($146.0M)	($86.0M)	($46.0M)	($27.0M)
Taxes paid on RSUs and net share settlements	($10.6M)	($10.5M)	($9.2M)	($6.3M)
Net cash provided by (used in) financing activities	($135.9M)	($93.2M)	($44.2M)	($163.5M)
Effect of exchange rate changes on cash and cash equivalents	($2.0M)	($797.0K)	($1.2M)	($1.4M)
Net change in cash and cash equivalents	$47.6M	$10.7M	($17.2M)	($11.1M)
Cash and cash equivalents at beginning of period	$162.2M	$162.2M	$162.2M	$151.8M
Cash and cash equivalents at end of period	$209.8M	$172.9M	$145.0M	$140.7M
Cash paid for income taxes	$42.4M	$36.7M	$30.8M	$55.9M
Cash paid for interest	$11.8M	$8.8M	$4.8M	$14.2M

Bio-Techne Corporation score and earnings-call analysis · All covered companies

Figures as reported in SEC filings. General information, not investment advice.